Menu Close

Transgender Women on Oral HIV Pre-Exposure Prophylaxis Have Significantly Lower Tenofovir and Emtricitabine Concentrations When Also Taking Oestrogen When Compared to Cisgender Men

Citation

Shieh, Eugenie; Marzinke, Mark A.; Fuchs, Edward J.; Hamlin, Allyson; Bakshi, Rahul; Aung, Wutyi; Breakey, Jennifer; Poteat, Tonia; Brown, Todd; & Bumpus, Namandjé N., et al. (2019). Transgender Women on Oral HIV Pre-Exposure Prophylaxis Have Significantly Lower Tenofovir and Emtricitabine Concentrations When Also Taking Oestrogen When Compared to Cisgender Men. Journal of the International AIDS Society, 22(11), e25405. PMCID: PMC6832671

Abstract

INTRODUCTION: Oral HIV Pre-Exposure Prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC) is highly effective. Transgender women (TGW) have increased HIV risk, but have been underrepresented in trials. For TGW on oestrogens for gender-affirming hormone treatment (GAHT), TDF/FTC-oestrogen interactions may negatively affect HIV prevention or gender-affirming goals. Our aim was to evaluate any pharmacokinetic drug-drug interaction between GAHT and TDF/FTC.

URL

http://dx.doi.org/10.1002/jia2.25405

Reference Type

Journal Article

Journal Title

Journal of the International AIDS Society

Author(s)

Shieh, Eugenie
Marzinke, Mark A.
Fuchs, Edward J.
Hamlin, Allyson
Bakshi, Rahul
Aung, Wutyi
Breakey, Jennifer
Poteat, Tonia
Brown, Todd
Bumpus, Namandjé N.
Hendrix, Craig W.

Year Published

2019

Volume Number

22

Issue Number

11

Pages

e25405

PMCID

PMC6832671

Reference ID

12852